Orthocell

21/04/2026

Tylah Tully sits down with Orthocell Managing Director and CEO Paul Anderson to discuss Orthocells growing traction in the US market, delivering strong revenue growth with expansion across key hospital networks.

Orthocell (ASX:OCC) gains traction in the US market, delivering strong revenue growth and expanding access across key hospital networks.

20/04/2026

Orthocell Ltd has today released its Quarterly Report for the quarter ended 31 March 2026, highlighting a period of continued revenue growth, strong US commercial traction and expanding global adoption of Remplir.

Key highlights for the quarter include:

✅ $3.2 million revenue achieved, driven primarily by Remplir’s growing pe*******on in existing markets and the commencement of material sales from the U.S.

✅ U.S. Remplir sales reached $300k in the March quarter, with $170k in Remplir sales recorded in March, providing early evidence of a potential revenue inflection point within the US$1.6 billion U.S. Remplir addressable market

✅ Year-to-date revenue of $9.4 million, up 45% on the prior corresponding period and already exceeds full-year FY25 revenue of $9.2M

✅ Strong cash position of $48 million, supporting ongoing commercial expansion

✅ Commercialisation of Remplir in the US continues to track ahead of expectations.

- Distribution network now covering 16+ states (~40% of US population)

- 32 VAC approvals providing access to 115+ hospitals (57 pending)

- 49 surgeons using Remplir, with 115 units sold in the quarter

✅ Real-world use of Remplir in defence settings continues to build momentum

- Growing validation in real-world settings, including 23 procedures in Ukraine

- Subsequent to the end of the quarter, approval was secured for use across US

- Department of Defence hospital networks, with first procedure already completed

✅ Progress in Canada commercial rollout, with initial sales expected shortly

✅ UK/EU regulatory pathway on track, with distributor appointment supporting market entry preparation

✅ Continued expansion of Remplir applications, including nerve-sparing prostate cancer surgery

Orthocell CEO and MD, Paul Anderson, said:

“This quarter reflects continued strong progress in the commercialisation of Remplir, particularly in the United States, where we are seeing growing surgeon adoption and increasing revenue contribution. The consistency of our revenue performance and the growth in key commercial metrics, including hospital uptake, surgeon utilisation and distributor expansion, is particularly encouraging. Notably, the acceleration in U.S. revenue in March provides early evidence of a potential inflection point as these commercial efforts begin to scale.

Read the ASX announcement: https://bit.ly/4cF9b3f

**

Investor Webinar | Join us today at 9am AWST/11am AEST

Join regenerative medicine company Orthocell Limited’s Chair John Van Der Wielen, CEO and MD Paul Anderson, and CFO Jim Piper for an investor briefing on Monday 20 April 2026. The session will include a review of the March quarter results and an operational update covering the U.S. rollout of Remplir™ and its use in prostate cancer surgery in Australia.

📆 Monday 20 April 2026
🕘 9:00am AWST | 11:00am AEST

Register to attend: https://us02web.zoom.us/webinar/register/WN_eJXEP9InTm6_Hra63gu9MA

**

$OCC

17/04/2026

Orthocell will be attending IDEM Singapore | 17–19 April 2026 this week, one of the leading international events for the dental industry.

Orthocell’s Vice President of Global Commercialisation & Professional Engagements, Gregor Maier, will be presenting again at the Henry Schein, Inc. booth (L11), sharing insights on the clinical application of Striate+™ and its role in supporting guided bone and tissue regeneration.

📍 Henry Schein Booth L11
🗓 18 April at 10:00am

Gregor’s session, “From Bench to Chair – Turning Translational Medicine into Implant Success,” will explore how regenerative technologies are being translated into practical clinical outcomes.

We look forward to connecting with clinicians, partners and industry colleagues across the region. If you’re attending IDEM Singapore, we hope to see you there.

17/04/2026

Orthocell was pleased to participate in the Ignite Partners Investment Summit in Hong Kong this week.

CEO & Managing Director Paul Anderson, together with Chairman John Van Der Wielen, engaged with institutional investors and industry participants from across the APAC region over two days of meetings and presentations.

The Summit provided a valuable opportunity to share an update on Orthocell’s growth strategy, including the continued US commercialisation of Remplir™ and the Company’s broader global expansion initiatives.

Orthocell appreciates the strong interest and engagement from the investment community and values the opportunity to further strengthen its presence across key international capital markets.

$OCC

17/04/2026

Orthocell (ASX:OCC) has shared that the first surgical case using Remplir™ has been successfully completed within the U.S. Department of Defense (DoD) / Veterans Affairs (VA) hospital network. This comes shortly after the Company’s announcement that it had received approval to supply Remplir into these hospital systems, including approximately 51 DoD military hospitals and 170 VA medical centres across the US.

This milestone marks the first clinical use of Remplir within the DoD/VA network, and represents an important step in Orthocell’s U.S commercialisation strategy, demonstrating the Company’s ability to rapidly translate regulatory and procurement approvals into real-world surgical adoption. The surgery was conducted at a military base hospital.

The rapid completion of a first surgical case highlights early engagement from surgeons within these systems and reinforces the strength of Orthocell’s existing U.S. distributor footprint, which spans 17 states and supports efficient onboarding and in‑theatre case support.

Orthocell Managing Director Paul Anderson said:

“We are extremely pleased to see Remplir translated into its first surgical case within the U.S. DoD and VA hospital network so quickly after receiving approval. It’s a strong validation of our commercial strategy and surgeon engagement efforts while demonstrating the value of our distribution network.

This milestone underscores both the clinical relevance of Remplir for complex nerve injuries and our team’s ability to execute rapidly once access is secured. Military and veteran healthcare systems manage some of the most challenging trauma cases, and early surgical uptake is an encouraging signal as we continue to expand activity across these hospitals.”

With expanding hospital access, growing surgeon engagement and increasing case activity, the Company continues to make excellent progress with its Remplir rollout across the U.S.

Read the ASX announcement: https://bit.ly/4mId7oE

$OCC

15/04/2026

Orthocell has secured approval for Remplir™ to be used across the United States Department of Defence (DoD) and Veterans Affairs (VA) hospital networks, providing access to approximately 51 DoD military hospitals and 170 VA medical centres.

This marks a significant milestone in the Company’s U.S. commercial strategy and builds on growing momentum in the market, with 32 Value Analysis Committee approvals already secured providing access to more than 115 hospitals, and a further 57 applications currently pending.

Orthocell will now leverage its established U.S. distributor network across 17 states to target military and VA surgeons operating within these hospital systems.

The approval follows recent clinical use of Remplir in 23 surgical procedures on injured soldiers in Ukraine, highlighting its real-world performance in conflict-related injuries and its suitability for the types of trauma commonly encountered in military healthcare settings.

Orthocell Managing Director Paul Anderson said:

“Securing access to the U.S. Department of Defence and Veterans Affairs hospital networks is a significant milestone for Orthocell and a major step forward in our U.S. commercial strategy.

“This approval enables us to engage directly with military and VA surgeons treating complex nerve injuries and to leverage our existing distributor network to drive adoption of Remplir across these key institutions.”

Read the ASX announcement: https://bit.ly/4el0cXk

$OCC

14/04/2026

Investor Webinar – Quarterly Results

Join regenerative medicine company Orthocell Limited’s Chair John Van Der Wielen, CEO and MD Paul Anderson, and CFO Jim Piper for an investor briefing on Monday 20 April 2026. The session will include a review of the March quarter results and an operational update covering the U.S. rollout of Remplir™ and its use in prostate cancer surgery in Australia.

📆 Monday 20 April 2026
🕘 9:00am AWST | 11:00am AEST
Register to attend: https://us02web.zoom.us/webinar/register/WN_eJXEP9InTm6_Hra63gu9MA

$OCC

10/04/2026

Orthocell are proud to sponsor the prestigious Premier's Science Awards, celebrating excellence across science, technology, engineering and mathematics in Western Australia.

Now in its 25th year, the awards recognise the researchers, educators and innovators driving progress and shaping the future of STEM.

We are committed to supporting innovation, advancing scientific outcomes and contributing to a thriving global research community.

We look forward to celebrating the incredible talent and achievements within WA’s STEM sector.

🔗 Learn more: https://bit.ly/4mqZY3c

$OCC

09/04/2026

📰 Media | StockwireX

Orthocell’s nerve repair product, Remplir™, has been highlighted in recent coverage by StockwireX, outlining its exemption from newly introduced US tariffs on medical devices.

The article reinforces the strategic importance of Remplir within the US market, with the exemption supporting continued access to this innovative nerve repair solution without additional cost burden.

As Orthocell advances its commercialisation efforts in the United States, this development further strengthens the Company’s position and ability to scale globally.

Orthocell Managing Director Paul Anderson said:
“The exemption ensures that Remplir remains competitively positioned in the US ...and supports our mission to deliver effective nerve repair solutions to patients and surgeons without disruption.”

Take a look: https://bit.ly/4c0Kcsf

$OCC

02/04/2026

Ignite Investment Summit | Hong Kong
15-16 April 2026

Orthocell (ASX: OCC) CEO and Managing Director Paul Anderson, together with Chairman John Van Der Wielen, will be attending the Ignite Investment Summit in Hong Kong next week.

The Summit brings together company leaders and institutional investors from across the APAC region for two days of targeted meetings, presentations and investor engagement.

Paul will present an update on Orthocell’s growth strategy, including the continued US commercialisation of Remplir™ and the Company’s broader global expansion.

The event provides an important opportunity to connect with international investors and further expand Orthocell’s presence across key capital markets.

Register for the event and book a meeting with $OCC here: https://weareignite.com/events/april-2026/

01/04/2026

Replay | Ausbiz Capital Investor Connect

Orthocell CEO and Managing Director Paul Anderson presented today at the Ausbiz Capital Investor Connect Biotech & Pharmaceuticals Special, where he provided an update on the Company’s commercial progress and global expansion strategy.

The presentation focused on the US rollout of Remplir™, where market access activities continue to progress as planned, supported by growing surgeon adoption and increasing sales momentum.

With expanding distribution, advancing VAC approvals and growing repeat usage, Orthocell remains focused on disciplined ex*****on as it scales its presence in the US nerve repair market.

Take a look: https://bit.ly/4sccjcL

29/03/2026

Upcoming Investor Events

Orthocell CEO and MD Paul Anderson will be presenting at the following investor events, outlining the Company’s global expansion strategy and the commercialisation of Remplir™ in the United States.

👉 Life Sciences WA | Broker Meets Biotech
🗓️ 31 March
⏰ 1.00pm -3.30pm AWST

More information coming soon here: https://bit.ly/3Puiviy

👉 Ausbiz | Capital Investor Connects
🗓️ 31 March
⏰ 9am AWST

Register your spot today: https://bit.ly/4bQeMDx

👉 Hong Kong Ignite Investment Summit
🗓️ 15 - 16 April 2026
📍 Grand Hyatt, Wan Chai | Hong Kong

If you're interested in scheduling a 30-minute meeting with Orthocell, please register here: https://weareignite.com/investor/

Join the sessions to learn more on the Company’s progress and future outlook.

$OCC